Global Cancer Gene Therapy Market Research and Forecast 2018-2023
Gene therapy is a process to treat or prevent disease replacing the mutated genes with healthy genes. This replacement allows the cells for the production of useful proteins. It can also change the way genes are generated. This enables under- or overactive genes to operate properly. Gene therapy can be used for expressing entirely foreign genes in cells that alter their function or survival. During cancer treatment, the genes are replaced for fighting against carcinogenic tumor cells. Cancer gene therapy inserts therapeutic DNA into the patient for the treatment of cancer. It is considered to be an effective treatment for cancer as it causes minimum side effects with maximum efficacy.
The factors that are contributing significantly to the growth of global cancer gene therapy market includes rising pool of population with cancer patients coupled with increasing geriatric population base. Globally there is rise in the cancer patients each year. According to the WHO cancer is considered to be the second leading cause of deaths in the year 2015. It is also estimated that that 1 death out of 6 deaths is caused by cancer. Rise in R&D activities owing to the extensive funding in the field of cancer gene therapy is another major factor for the prevalence of cancer gene therapy. However, high cost of the treatment is a factor that has negative impact on the growth of the market.
The cancer gene therapy market can be segmented on the basis of therapy and end users. Based on the therapy, the cancer gene therapy market is bifurcated as gene transfer immunotherapy, oncolytic virotherapy and gene induced immunotherapy. The gene induced immunotherapy is further segmented as delivery of cytokines gene and delivery of tumor antigen gene. On the basis of end users, the global cancer gene therapy market is diversified as hospitals, research institutes and biotech companies.
The global cancer gene therapy market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The regions analyzed in the report involve North America, Europe, APAC and Rest of the World. The North America is expected to be dominating in the cancer gene therapy market owing to the presence of high quality healthcare infrastructure. In addition, presence of large pool of cancer patients and aging population in the region is another factor responsible for the regional growth. Europe is another significant market and holds a considerable market share in the global cancer gene therapy market.
Some of the players operating in the global cancer gene therapy market are Merck & Co., Inc., Bluebird bio Inc., Celgene Corporation and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For an instance, Celgene Corporation in July 2015 entered into a strategic immuno-oncology collaboration with BeiGene, Ltd. for advancing PD-1 Inhibitor program for solid tumor cancers.
RESEARCH METHODOLOGY
The market study of cancer gene therapy market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as American College of Rheumatology, American Association for Clinical Chemistry (AACC), and American Autoimmune Related Diseases Association (AARDA), among others.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for drug manufacturers, healthcare provider, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global Cancer gene therapy market is segmented on the basis of regional outlook and following segments:
Global Cancer gene therapy Market Research and Analysis, By Therapy
Global Cancer gene therapy Market Research and Analysis, By End Users
Global Cancer gene therapy Market Research and Analysis, By Region
THE REPORT COVERS:
Comprehensive research methodology of global cancer gene therapy
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global cancer gene therapy market.
Insights about market determinants which are stimulating the global cancer gene therapy market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
The factors that are contributing significantly to the growth of global cancer gene therapy market includes rising pool of population with cancer patients coupled with increasing geriatric population base. Globally there is rise in the cancer patients each year. According to the WHO cancer is considered to be the second leading cause of deaths in the year 2015. It is also estimated that that 1 death out of 6 deaths is caused by cancer. Rise in R&D activities owing to the extensive funding in the field of cancer gene therapy is another major factor for the prevalence of cancer gene therapy. However, high cost of the treatment is a factor that has negative impact on the growth of the market.
The cancer gene therapy market can be segmented on the basis of therapy and end users. Based on the therapy, the cancer gene therapy market is bifurcated as gene transfer immunotherapy, oncolytic virotherapy and gene induced immunotherapy. The gene induced immunotherapy is further segmented as delivery of cytokines gene and delivery of tumor antigen gene. On the basis of end users, the global cancer gene therapy market is diversified as hospitals, research institutes and biotech companies.
The global cancer gene therapy market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The regions analyzed in the report involve North America, Europe, APAC and Rest of the World. The North America is expected to be dominating in the cancer gene therapy market owing to the presence of high quality healthcare infrastructure. In addition, presence of large pool of cancer patients and aging population in the region is another factor responsible for the regional growth. Europe is another significant market and holds a considerable market share in the global cancer gene therapy market.
Some of the players operating in the global cancer gene therapy market are Merck & Co., Inc., Bluebird bio Inc., Celgene Corporation and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For an instance, Celgene Corporation in July 2015 entered into a strategic immuno-oncology collaboration with BeiGene, Ltd. for advancing PD-1 Inhibitor program for solid tumor cancers.
RESEARCH METHODOLOGY
The market study of cancer gene therapy market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as American College of Rheumatology, American Association for Clinical Chemistry (AACC), and American Autoimmune Related Diseases Association (AARDA), among others.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for drug manufacturers, healthcare provider, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global Cancer gene therapy market is segmented on the basis of regional outlook and following segments:
Global Cancer gene therapy Market Research and Analysis, By Therapy
Global Cancer gene therapy Market Research and Analysis, By End Users
Global Cancer gene therapy Market Research and Analysis, By Region
THE REPORT COVERS:
Comprehensive research methodology of global cancer gene therapy
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global cancer gene therapy market.
Insights about market determinants which are stimulating the global cancer gene therapy market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
CHAPTER 1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. RULES & REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. JAPAN
2.3.1.5. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISING POOL OF POPULATION WITH CANCER PATIENTS
3.1.2. INCREASING FUNDING IN R&D OF CANCER GENE THERAPY
3.1.3. RISING GERIATRIC POPULATION BASE
3.1.4. TECHNOLOGICAL ADVANCEMENT SUCH AS CAR T-CELL THERAPY
3.2. RESTRAINTS
3.2.1. HIGH COST OF TREATMENT
3.3. OPPORTUNITIES
3.3.1. UNTAPPED MARKET IN EMERGING ECONOMIES
3.3.2. PARTNERSHIP & COLLABORATIONS AMONG THE PLAYERS TO DEVELOP AND LAUNCH GENE THERAPY PRODUCTS
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY
4.1.1. GENE TRANSFER IMMUNOTHERAPY
4.1.2. ONCOLYTIC VIROTHERAPY
4.1.3. GENE INDUCED IMMUNOTHERPAY
4.1.3.1. DELIVERY OF CYTOKINES GENE
4.1.3.2. DELIVERY OF TUMOR ANTIGEN GENE
4.2. GLOBAL CANCER GENE THERAPY BY END USERS
4.2.1. HOSPITALS
4.2.2. RESEARCH INSTITUTES
4.2.3. BIOTECH COMPANIES
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY COMPANY ANALYSIS
5.2. KEY STRATEGY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ACHILLES THERAPEUTICS LTD.
7.2. ADAPTIMMUNE THERAPEUTICS PLC
7.3. AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC.
7.4. ANI PHARMACEUTICALS, INC.
7.5. AUTOLUS THERAPEUTICS PLC
7.6. AVROBIO INC.
7.7. BEIGENE, LTD.
7.8. BIOCANCELL THERAPEUTIC
7.9. BLUEBIRD BIO, INC.
7.10. CELGENE CORPORATION
7.11. CELL MEDICA LTD.
7.12. EFFECTOR THERAPEUTICS, INC
7.13. FORMULA PHARMACEUTICALS, INC.
7.14. GENPREX, INC.
7.15. GENVEC INC.
7.16. GLAXOSMITHKLINE PLC
7.17. ILLUMINA, INC.
7.18. INOVIO PHARMACEUTICALS, INC.
7.19. JOUNCE THERAPEUTICS, INC.
7.20. KITE PHARMA, INC.
7.21. MERCK & COMPANY, INC.
7.22. MORPHOGENESIS, INC.
7.23. NOVARTIS AG
7.24. ONCOGENEX PHARMACEUTICALS, INC.
7.25. OXFORD BIOMEDICA PLC
7.26. PFIZER INC.
7.27. PSIOXUS THERAPEUTICS LTD
7.28. SANGAMO THERAPEUTICS, INC.
7.29. SIRION BIOTECH GMBH
7.30. SPARK THERAPEUTICS INC.
7.31. SYNERGENE THERAPEUTICS, INC.
7.32. UNUM THERAPEUTICS INC.
7.33. VASCULAR BIOGENICS LTD
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. RULES & REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. JAPAN
2.3.1.5. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISING POOL OF POPULATION WITH CANCER PATIENTS
3.1.2. INCREASING FUNDING IN R&D OF CANCER GENE THERAPY
3.1.3. RISING GERIATRIC POPULATION BASE
3.1.4. TECHNOLOGICAL ADVANCEMENT SUCH AS CAR T-CELL THERAPY
3.2. RESTRAINTS
3.2.1. HIGH COST OF TREATMENT
3.3. OPPORTUNITIES
3.3.1. UNTAPPED MARKET IN EMERGING ECONOMIES
3.3.2. PARTNERSHIP & COLLABORATIONS AMONG THE PLAYERS TO DEVELOP AND LAUNCH GENE THERAPY PRODUCTS
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY
4.1.1. GENE TRANSFER IMMUNOTHERAPY
4.1.2. ONCOLYTIC VIROTHERAPY
4.1.3. GENE INDUCED IMMUNOTHERPAY
4.1.3.1. DELIVERY OF CYTOKINES GENE
4.1.3.2. DELIVERY OF TUMOR ANTIGEN GENE
4.2. GLOBAL CANCER GENE THERAPY BY END USERS
4.2.1. HOSPITALS
4.2.2. RESEARCH INSTITUTES
4.2.3. BIOTECH COMPANIES
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY COMPANY ANALYSIS
5.2. KEY STRATEGY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ACHILLES THERAPEUTICS LTD.
7.2. ADAPTIMMUNE THERAPEUTICS PLC
7.3. AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC.
7.4. ANI PHARMACEUTICALS, INC.
7.5. AUTOLUS THERAPEUTICS PLC
7.6. AVROBIO INC.
7.7. BEIGENE, LTD.
7.8. BIOCANCELL THERAPEUTIC
7.9. BLUEBIRD BIO, INC.
7.10. CELGENE CORPORATION
7.11. CELL MEDICA LTD.
7.12. EFFECTOR THERAPEUTICS, INC
7.13. FORMULA PHARMACEUTICALS, INC.
7.14. GENPREX, INC.
7.15. GENVEC INC.
7.16. GLAXOSMITHKLINE PLC
7.17. ILLUMINA, INC.
7.18. INOVIO PHARMACEUTICALS, INC.
7.19. JOUNCE THERAPEUTICS, INC.
7.20. KITE PHARMA, INC.
7.21. MERCK & COMPANY, INC.
7.22. MORPHOGENESIS, INC.
7.23. NOVARTIS AG
7.24. ONCOGENEX PHARMACEUTICALS, INC.
7.25. OXFORD BIOMEDICA PLC
7.26. PFIZER INC.
7.27. PSIOXUS THERAPEUTICS LTD
7.28. SANGAMO THERAPEUTICS, INC.
7.29. SIRION BIOTECH GMBH
7.30. SPARK THERAPEUTICS INC.
7.31. SYNERGENE THERAPEUTICS, INC.
7.32. UNUM THERAPEUTICS INC.
7.33. VASCULAR BIOGENICS LTD
LIST OF TABLES
TABLE 1 GLOBAL CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL GENE TRANSFER IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL ONCOLYTIC VIROTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL GENE INDUCED IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL BIOTECH COMPANIES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 9 NORTH AMERICAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 10 NORTH AMERICAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
TABLE 11 NORTH AMERICAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 12 EUROPEAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 13 EUROPEAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
TABLE 14 EUROPEAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 15 APAC CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 16 APAC CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
TABLE 17 APAC CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 18 ROW CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
TABLE 19 ROW CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 1 GLOBAL CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL GENE TRANSFER IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL ONCOLYTIC VIROTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL GENE INDUCED IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL BIOTECH COMPANIES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 9 NORTH AMERICAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 10 NORTH AMERICAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
TABLE 11 NORTH AMERICAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 12 EUROPEAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 13 EUROPEAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
TABLE 14 EUROPEAN CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 15 APAC CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 16 APAC CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
TABLE 17 APAC CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 18 ROW CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY THERAPY, 2017-2023 ($ MILLION)
TABLE 19 ROW CANCER GENE THERAPY MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL CANCER GENE THERAPY MARKET SHARE BY THERAPY, 2017 VS 2023 (%)
FIGURE 2 GLOBAL CANCER GENE THERAPY MARKET SHARE BY END USERS, 2017 VS 2023 (%)
FIGURE 3 US CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 4 CANADA CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 5 UK CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 FRANCE CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 GERMANY CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 ITALY CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 SPAIN CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 ROE CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 INDIA CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 CHINA CANCER GENE THERAPY MARKETSIZE, 2017-2023 ($ MILLION)
FIGURE 13 JAPAN CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 14 ROAPAC CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 15 REST OF THE WORLD CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ACHILLES THERAPEUTICS LTD.
2. ADAPTIMMUNE THERAPEUTICS PLC
3. AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC.
4. ANI PHARMACEUTICALS, INC.
5. AUTOLUS THERAPEUTICS PLC
6. AVROBIO INC.
7. BEIGENE, LTD.
8. BIOCANCELL THERAPEUTIC
9. BLUEBIRD BIO, INC.
10. CELGENE CORPORATION
11. CELL MEDICA LTD.
12. EFFECTOR THERAPEUTICS, INC
13. FORMULA PHARMACEUTICALS, INC.
14. GENPREX, INC.
15. GENVEC INC.
16. GLAXOSMITHKLINE PLC
17. ILLUMINA, INC.
18. INOVIO PHARMACEUTICALS, INC.
19. JOUNCE THERAPEUTICS, INC.
20. KITE PHARMA, INC.
21. MERCK & COMPANY, INC.
22. MORPHOGENESIS, INC.
23. NOVARTIS AG
24. ONCOGENEX PHARMACEUTICALS, INC.
25. OXFORD BIOMEDICA PLC
26. PFIZER INC.
27. PSIOXUS THERAPEUTICS LTD
28. SANGAMO THERAPEUTICS, INC.
29. SIRION BIOTECH GMBH
30. SPARK THERAPEUTICS INC.
31. SYNERGENE THERAPEUTICS, INC.
32. UNUM THERAPEUTICS INC.
33. VASCULAR BIOGENICS LTD
FIGURE 1 GLOBAL CANCER GENE THERAPY MARKET SHARE BY THERAPY, 2017 VS 2023 (%)
FIGURE 2 GLOBAL CANCER GENE THERAPY MARKET SHARE BY END USERS, 2017 VS 2023 (%)
FIGURE 3 US CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 4 CANADA CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 5 UK CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 FRANCE CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 GERMANY CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 ITALY CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 SPAIN CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 ROE CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 INDIA CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 CHINA CANCER GENE THERAPY MARKETSIZE, 2017-2023 ($ MILLION)
FIGURE 13 JAPAN CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 14 ROAPAC CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 15 REST OF THE WORLD CANCER GENE THERAPY MARKET SIZE, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ACHILLES THERAPEUTICS LTD.
2. ADAPTIMMUNE THERAPEUTICS PLC
3. AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC.
4. ANI PHARMACEUTICALS, INC.
5. AUTOLUS THERAPEUTICS PLC
6. AVROBIO INC.
7. BEIGENE, LTD.
8. BIOCANCELL THERAPEUTIC
9. BLUEBIRD BIO, INC.
10. CELGENE CORPORATION
11. CELL MEDICA LTD.
12. EFFECTOR THERAPEUTICS, INC
13. FORMULA PHARMACEUTICALS, INC.
14. GENPREX, INC.
15. GENVEC INC.
16. GLAXOSMITHKLINE PLC
17. ILLUMINA, INC.
18. INOVIO PHARMACEUTICALS, INC.
19. JOUNCE THERAPEUTICS, INC.
20. KITE PHARMA, INC.
21. MERCK & COMPANY, INC.
22. MORPHOGENESIS, INC.
23. NOVARTIS AG
24. ONCOGENEX PHARMACEUTICALS, INC.
25. OXFORD BIOMEDICA PLC
26. PFIZER INC.
27. PSIOXUS THERAPEUTICS LTD
28. SANGAMO THERAPEUTICS, INC.
29. SIRION BIOTECH GMBH
30. SPARK THERAPEUTICS INC.
31. SYNERGENE THERAPEUTICS, INC.
32. UNUM THERAPEUTICS INC.
33. VASCULAR BIOGENICS LTD
